Journals / Türk Üroloji Dergisi/Turkish Journal of Urology / 2003 / Cilt: 29 - Sayı: 4

Our results of RPLND on metastatic nonseminomatous testis tumors after chemoteraphy

Metastatik nonseminomatöz testis tümörlerinde kemoterapi sonrası RPLND sonuçlarımız

Pages
393–397
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, while these deciding, doctors should evaluate these criteria for each patient separately, because each criteria is of a different importance for each patient.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: In metastatic nonseminomatous testis cancer, there are certain criteria which can be used to choose patient for RPLND after chemotherapy.
📊
Key Findings & Data:Materials and Methods: After standard chemoterapy, RPLND was performed to 10 patients with tumor markers normal level (AFP and ßHCG) and with a residual mass greater than 2 cm in retroperitoneal on CT.
💡
Conclusion & Impact:However, while these deciding, doctors should evaluate these criteria for each patient separately, because each criteria is of a different importance for each patient.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Testis neoplazmları · Lenf düğümü çıkartılması · Retroperitoneal alan

Abstract

Introduction: In metastatic nonseminomatous testis cancer, there are certain criteria which can be used to choose patient for RPLND after chemotherapy. We evaluated our results using these criteria. Materials and Methods: After standard chemoterapy, RPLND was performed to 10 patients with tumor markers normal level (AFP and ßHCG) and with a residual mass greater than 2 cm in retroperitoneal on CT. We enrolled orchiectomy histopàthology, tumor markers after orchiectomy, size of retroperitoneal mass on CT before and after chemotherapy. Dissection material was compared with orchiectomy histopàthology. Results: Bilateral full template RPLND was performed on 9 of the patients and partial resection had one patient. We determined in dissection material that 4 had necrosis and fibrosis and 4 had terotoma and 2 had viable germ cell cancer. One patient who went though partial resection died 22 months later due to testis cancer and, no pathologic results were found in other patients during follow up. Conclusion: In patients with metastatic nonseminomatous testis cancer, certain criteria must be used in order to decide for RPLND after chemotherapy. However, while these deciding, doctors should evaluate these criteria for each patient separately, because each criteria is of a different importance for each patient.

Özet

Metastatik nonseminomatöz testis tümörlerinde, kemoterapi sonrası RPLND (Retroperitoneal Lenf Nod Diseksiyonu) için hasta seçiminde kullanılabilecek belirli kriterler vardır. Biz de, bu kriterleri kullanarak sonuçlarımızı değerlendirdik. Standart kemoterapi sonrası tümör belirleyicileri (AFP ve ßHCG) normal sınırlarda ve BT'de 2 cm'den büyük retroperitoneal artık (rezidüel) kitlesi olan 10 hastaya RPLND yapıldı. Bu hastaların primer patolojisi, orşiektomi öncesi tümör belirleyicileri, kemoterapi öncesi ve sonrası retroperitoneal kitlenin BT'deki çapları kaydedildi. RPLND materyali ile primer testis histopatolojisi karşılaştırıldı. 9 hastaya bilateral full template RPLND ve bir hastaya da parsiyel kitle rezeksiyon yapıldı. RPLND'nin histopatolojik incelemesinde; 4 olguda (%40) nekroz ve fibrosiz, 4 olguda (%40) teratom ve 2 olguda (%20) canlı germ hücre metastazı saptandı. Parsiyel rezeksiyon yaptığımız bir hasta RPLND'den 22 ay sonra hastalık nedeniyle kaybedildi. Kalan 9(%90) hastanın hiç birinde takipleri süresince hastalığa bağlı bir bulgu saptanmadı. Metastatik nonseminomatöz testis tümörlü hastalarda kemoterapi sonrası RPLND kararının verilmesinde belirlenmiş kriterler kullanılmalıdır. Fakat verilecek bu kararlarda, hekim her hasta için bu kriterleri birbirinden bağımsız olarak değerlendirmelidir. Çünkü her bir kriter her hasta için farklı önem taşımaktadır.

🔖

Cite This Article

KARADEMİR, A. K., ŞENKUL, T., BAYKAL, K., ŞEN, B., İŞERİ, C., ERDEN, D. (2003). Our results of RPLND on metastatic nonseminomatous testis tumors after chemoteraphy. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 29 - Sayı: 4, 393–397. https://ajindex.com/articles/328511

References (7)

  1. Horwich A, Norman A, Fisher C: Primary chemotherapy for stage II nonseminomatous germ cell tumors of testis. J Urol 151
  2. 72, 1994 2- Toner GC, Panicek DM, Heelan RT: Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: Recommendations for patients selection. J Clin Oncol
  3. 1683, 1990 3- Mulders PF, Oosterhof GON, Boetes C: The importance of prognostic factors in the individual treatment of patients with disseminated germ cell tumors. Br J Urol 66: 425, 1990 4- Vergouwe Y, Steyerberg EW, Foster RS, Habbema DF, Donohue JP: Validation of a predicttion model and its predictors for the histology of residual masses in nonseminomatous testicular cancer. J Urol 165
  4. 88, 2001 5- Donohue JP, Rowland RG, Birhle RG: Transabdominal retroperitoneal lymh node dissection. In Skinner DG
  5. Lieskovksy G, Eds: Diagnosis and management of genitourinary cancer. Philadelphia W.B. Saunders, pp 802-916, 1988 6- International germ cell cancer collaborative group: International germ cell consensus classification: A prognostic factors-based staging system for metastatic germ cell cancers. J Clin Oncol 15: 594, 1997 7- Schultz S, Einhorn L, Conces D: Management of post chemotherapy residual mass in patients with advenced nonseminoma: Indiana University experience. J Clin Oncol 7
  6. 1497, 1989 8- Donohue JP, Rowland RG: The role of surgery in advanced testicular cancer. Cancer 54: 2716, 1984 9- Divrik T, Zorlu F, Ok M: Metastatik nonsemi-nomatöz germ hücreli tümörlerde kemoterapi sonrası cerrahi. Üroloji Bülteni 9: 72-76, 1998 10- Donohue JP, Rowland RG, Kopecky K: Correlation of computarized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after che-moterapy for testis cancer. J Urol 137:1176, 1987 11- Üstün M, Heilo A, Fossa DS, Aass N, BernerA: Ultrasound-guide fine needle cytology of retrope-ritoneal masses in patients with malignancy germ cell tumors: Diagnosis and therapeutic impact. Eur Urol 42
  7. 228, 2002 12- Foster RS, Donohue JP: Can retroperitoneal lympadenectomy be omitted in some patients after chemotherapy. Urol Clin North Am 25(3): 479-84, 1998 13- Debono D, Heilman D, Einhorn L: Decision analysis for avoiding post chemotherapy surgery in patients with disseminated nonseminomatous germ cell. J Clin Oncol 14: 1765, 1996 14- Tekgül S, Özen HA, Çelebi İ: Postchemotera-puetic surgery for metastatic testicular germ cell tumors: Results of extended primary chemothreapy in limited su